Psoriasis and Its Link to Increased Sleep Disorder Risks
Emerging research reveals a strong link between psoriasis and increased risk of sleep disorders, underscoring the importance of integrated care for affected patients.
Recent research highlights a significant association between psoriasis, regardless of severity, and a higher likelihood of developing sleep disorders. Published online on May 13 in JEADV Clinical Practice, the study emphasizes that both mild and moderate-to-severe psoriasis are linked to conditions such as restless leg syndrome, insomnia, and obstructive sleep apnea.
The study, led by Michael J. Diaz of the College of Medicine at the University of Florida in Gainesville, analyzed data from 7,743 adults with psoriasis extracted from the All of Us database. These individuals were matched with controls based on age, sex, and race/ethnicity. Findings revealed that even mild psoriasis increases the risk for sleep issues, with stronger associations noted among those with moderate-to-severe disease.
Importantly, the research also uncovered that the risk for sleep disorders was particularly elevated among non-White patients, especially concerning insomnia and obstructive sleep apnea. The study underscores the importance of personalized and culturally sensitive approaches in managing psoriasis and its related health complications.
Study limitations include reliance on electronic health records, which might lead to diagnostic misclassification, and some authors disclosed connections to the biopharmaceutical industry.
This research emphasizes the need for clinicians to monitor sleep health in psoriasis patients and adopt comprehensive management strategies to improve overall quality of life.
Source: https://medicalxpress.com/news/2025-06-psoriasis-disorders.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Novel Mechanism Linking Mitochondrial Dysfunction to Obesity-Related Insulin Resistance
Scientists have discovered a specific mitochondrial dysfunction in the liver that plays a key role in obesity-related insulin resistance and type 2 diabetes, opening new avenues for targeted therapies.
Lecanemab: A Well-Tolerated Treatment for Early-Stage Alzheimer's Disease in Real-World Settings
Recent studies indicate that lecanemab, an Alzheimer's drug, is safe and well tolerated outside clinical trials, especially when administered in specialized outpatient clinics. The treatment can slow disease progression with minimal risk of severe side effects, particularly in patients with early-stage Alzheimer's.
